Form 4: Director Ivana Magovcevic-Liebisch Acquires Acrivon Therapeutics Stock

Director Ivana Magovcevic-Liebisch acquired 9,366 restricted stock units of Acrivon Therapeutics, Inc. (ACRV) on May 18, 2026, with full vesting expected on May 18, 2027.

Summary

• Ivana Magovcevic-Liebisch, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per RSU.
• The RSUs are scheduled to vest in full on May 18, 2027, provided the Reporting Person remains in continuous service with the company through that date.
• The acquisition was reported on May 20, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard equity grant to a director, indicating continued engagement and potential confidence, but does not reflect new financial performance or strategic shifts.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 9,366 RSUs indicates a significant grant to a key executive.

Risks

• The RSUs are subject to vesting conditions, meaning the director must remain employed until May 18, 2027, to fully realize the benefit.
• The value of the acquired RSUs is tied to the future performance and stock price of Acrivon Therapeutics, Inc.

Future Outlook

The acquired RSUs are set to vest in full on May 18, 2027, contingent upon the Reporting Person's continued employment with Acrivon Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of RSUs by a director, are closely watched by the market as potential indicators of management's confidence in the company's trajectory. This type of equity grant is a common form of executive compensation tied to long-term performance and retention.

Stakeholder Impact

• Shareholders: May interpret the director's acquisition of RSUs as a positive signal of confidence in the company's future, potentially influencing investment decisions.
• Employees: The grant of RSUs to a director is a standard compensation practice and does not directly impact other employees, though it reflects the company's compensation philosophy.
• Management: Reinforces the alignment of executive incentives with long-term company performance.

Next Steps

• Monitoring the continuous service of Ivana Magovcevic-Liebisch through May 18, 2027, for the vesting of RSUs.
• Observing future stock performance of Acrivon Therapeutics, Inc.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Trading, Restricted Stock Units, RSU, Director, Securities Ownership, Stock Vesting